問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

China Medical University Hospital

List

1858Cases

2024-02-12 - 2026-06-01

Phase III

Active
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjogren's Syndrome With Moderate-to-Severe Symptom State

  • Condition/Disease

    Sjogren's Syndrome

  • Test Drug

    Dazodalibep

Participate Sites
5Sites

Recruiting5Sites

2018-09-01 - 2026-10-02

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2017-07-18 - 2026-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-06-01 - 2025-03-28

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-12-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-06-13 - 2030-06-30

Phase III

Active
An Open-label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants with Primary Membranous Nephropathy (PMN) [PROMINENT]

  • Condition/Disease

    Primary Membranous Nephropathy (PMN)

  • Test Drug

    powder

Participate Sites
10Sites

Recruiting10Sites

2025-09-01 - 2029-12-31

Phase III

Active
A Multicenter, Long-term, Randomized, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants with Sjögren’s Syndrome (SS)

  • Condition/Disease

    Sjögren’s Syndrome (SS)

  • Test Drug

    Injection

Participate Sites
5Sites

Recruiting5Sites

2025-07-01 - 2030-10-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-06-30 - 2030-12-31

Phase III

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
7Sites

Recruiting7Sites

2023-03-01 - 2028-10-16

Phase III

Active
An Expanded Access Program of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria

  • Condition/Disease

    Paroxysmal Nocturnal Hemoglobinuria

  • Test Drug

    PozelimabCemdisiran

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

1 37 38 39 40 41 186
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB